Structure optimization of Cmpd-15 as negative allosteric modulators for the β₂-adrenergic receptor

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• The beta-2 adrenergic receptor (β2AR) is a key target for various therapeutic interventions.
• Negative allosteric modulators (NAMs) offer a precise way to modulate receptor function.
• Identifying novel β2AR NAMs with improved pharmacological profiles is an ongoing research objective.

Purpose of the Study:

• To design and synthesize novel pyrazole derivatives as potential β2AR NAMs.
• To evaluate the allosteric antagonistic activity of these compounds on the β2AR.
• To assess the drug-like properties of the synthesized pyrazole derivatives.

Main Methods:

• Synthesis of 19 derivatives of 1-benzyl-3-arylpyrazole-5-carboxamides and 5 derivatives of 1-benzyl-5-arylpyrazole-3-carboxamides.
• Screening of synthesized compounds on the G-protein dependent signaling pathway of β2AR.
• Comparative analysis of antagonistic activity and drug-like profiles against a known β2AR NAM (Cmpd-15).

Main Results:

• The majority of 1-benzyl-3-arylpyrazole-5-carboxamide derivatives exhibited potent allosteric antagonistic activity against β2AR, surpassing Cmpd-15.
• 1-benzyl-5-arylpyrazole-3-carboxamide derivatives showed minimal to no allosteric antagonistic activity.
• Active pyrazole derivatives demonstrated relatively better drug-like profiles compared to Cmpd-15.

Conclusions:

• A series of 1-benzyl-3-arylpyrazole-5-carboxamide derivatives were identified as a novel scaffold for β2AR NAMs.
• These compounds represent promising candidates for further development as therapeutic agents targeting β2AR.
• The study highlights the potential of specific pyrazole carboxamide structures in modulating β2AR signaling.